Yorktown Management & Research Company’s Ligand Pharmaceuticals LGND Stock Holding History

Yorktown Management & Research Company’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Buy	+1,300	New	+$306K	0.25%	153

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Yorktown Management & Research Company's LGND Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 1,300 shares worth $411K. The stake represents 0.25% of the portfolio and ranks #153 among its holdings.

205 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Yorktown Management & Research Company held 1,300 shares of Ligand Pharmaceuticals worth $411K as of Q2 2026.
Ligand Pharmaceuticals was a new Yorktown Management & Research Company position in Q2 2026.
Ligand Pharmaceuticals made up 0.25% of Yorktown Management & Research Company's portfolio in Q2 2026, its #153 holding.
205 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.